Cargando…

Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer

Gene expression (GE) signatures and Tumor Infiltrating Lymphocytes (TIL) enumeration are predictive for response to neoadjuvant chemotherapy in HR- and in HER2+ breast cancer, but data are conflicting in HR+/HER2- disease. This study aimed to explore their predictive value in this subset, measured b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matikas, Alexios, Lövrot, John, Ramberg, Anna, Eriksson, Margareta, Lindsten, Therese, Lekberg, Tobias, Hedenfalk, Ingrid, Loman, Niklas, Bergh, Jonas, Hatschek, Thomas, Erlandsson, Ann, Foukakis, Theodoros
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6140817/ https://www.ncbi.nlm.nih.gov/pubmed/30228933 http://dx.doi.org/10.1080/2162402X.2018.1466017

Ejemplares similares

Immune gene expression and response to chemotherapy in advanced breast cancer
por: Foukakis, Theodoros, et al.
Publicado: (2018)

Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer
por: Matikas, A., et al.
Publicado: (2021)

Expression patterns and prognostic implications of tumor-infiltrating lymphocytes dynamics in early breast cancer patients receiving neoadjuvant therapy: A systematic review and meta-analysis
por: Zhu, Yajing, et al.
Publicado: (2022)

Effect of macrophages on breast cancer cell proliferation, and on expression of hormone receptors, uPAR and HER-2
por: Lindsten, Therése, et al.
Publicado: (2017)

Assessment of early response biomarkers in relation to long‐term survival in patients with HER2‐negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial
por: Kimbung, Siker, et al.
Publicado: (2017)

An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression
por: Palazon, Asis, et al.
Publicado: (2017)

PD-1 protein and gene expression as prognostic factors in early breast cancer
por: Matikas, Alexios, et al.
Publicado: (2020)

Dissecting Tumor-Immune Microenvironment in Breast Cancer at a Spatial and Multiplex Resolution
por: Tzoras, Evangelos, et al.
Publicado: (2022)

Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
por: Chrétien, Sebastian, et al.
Publicado: (2019)

Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations
por: Zerdes, Ioannis, et al.
Publicado: (2018)

Women with short survival after diagnosis of metastatic breast cancer: a population-based registry study
por: Boman, Caroline, et al.
Publicado: (2022)

The interplay between eosinophils and T cells in breast cancer immunotherapy
por: Zerdes, Ioannis, et al.
Publicado: (2023)

Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers
por: Haugen, Mads H., et al.
Publicado: (2021)

Discordance of PD-L1 Expression at the Protein and RNA Levels in Early Breast Cancer
por: Zerdes, Ioannis, et al.
Publicado: (2021)

Chemotherapy use near the end-of-life in patients with metastatic breast cancer
por: Edman Kessler, Luisa, et al.
Publicado: (2020)

Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?
por: Matikas, A, et al.
Publicado: (2019)

Programmed death‐ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21‐gene and 70‐gene signatures in estrogen receptor‐positive disease
por: Zerdes, Ioannis, et al.
Publicado: (2020)

Validation of a novel procedure for quantification of the formation of phosphoramide mustard by individuals treated with cyclophosphamide
por: von Stedingk, Hans, et al.
Publicado: (2014)

Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study
por: Zerdes, Ioannis, et al.
Publicado: (2021)

Infiltrating immune cells in prostate cancer tissue after androgen deprivation and radiotherapy
por: Erlandsson, Ann, et al.
Publicado: (2023)

Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer
por: Matikas, Alexios, et al.
Publicado: (2017)

Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival
por: Tobin, N. P., et al.
Publicado: (2015)

Infiltration of M2 Macrophages and Regulatory T Cells Plays a Role in Recurrence of Renal Cell Carcinoma
por: Davidsson, Sabina, et al.
Publicado: (2020)

Comedications influence immune infiltration and pathological response to neoadjuvant chemotherapy in breast cancer
por: Hamy, Anne-Sophie, et al.
Publicado: (2019)

Immune repertoire and responses to neoadjuvant TCHP therapy in HER2-positive breast cancer
por: Shin, Junyoung, et al.
Publicado: (2023)

Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer
por: Luque, Melani, et al.
Publicado: (2022)

HER-2 Expression in Colorectal Cancer and Its Correlation with Immune Cell Infiltration
por: Yang, Di, et al.
Publicado: (2023)

A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways
por: Hamy, Anne-Sophie, et al.
Publicado: (2016)

Correlation Between Immune-Related Genes and Tumor-Infiltrating Immune Cells With the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer
por: Zhou, Yan, et al.
Publicado: (2022)

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
por: Loibl, Sibylle, et al.
Publicado: (2022)

Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer
por: Griguolo, G., et al.
Publicado: (2021)

Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter Study
por: Kjällquist, Una, et al.
Publicado: (2022)

Therapeutic Effect of Trastuzumab in Neoadjuvant-Treated HER2-Positive Breast Cancer with Low Infiltrating Level of Tumor-Infiltrating Lymphocytes
por: Liu, Shiwei, et al.
Publicado: (2020)

Residual disease and immune infiltration as a new surrogate endpoint for TNBC post neoadjuvant chemotherapy
por: Luen, Stephen L., et al.
Publicado: (2019)

The mannosylated extracellular domain of Her2/neu produced in P. pastoris induces protective antitumor immunity
por: Dimitriadis, Alexios, et al.
Publicado: (2009)

Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer – A Substudy of the Neoadjuvant GeparQuinto Trial
por: Issa-Nummer, Yasmin, et al.
Publicado: (2013)

Pancreatic Ductal Adenocarcinoma Contains an Effector and Regulatory Immune Cell Infiltrate that Is Altered by Multimodal Neoadjuvant Treatment
por: Shibuya, Kendall C., et al.
Publicado: (2014)

Effect of neoadjuvant chemotherapy on tumor immune infiltration in breast cancer patients: Systematic review and meta-analysis
por: Llano-León, Manuela, et al.
Publicado: (2023)

ESMO20 YO for YO: highlights on immune checkpoint blockade for triple-negative breast cancer
por: Punie, K., et al.
Publicado: (2020)

STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer
por: Zerdes, Ioannis, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5s4629p0mi0ik7o6ug9u9vlg9v